Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Emanuela Fantinel
Observed names:
E Fantinel,
E. Fantinel,
Fantinel, Emanuela
Institutions:
University of Verona,
Azienda Ospedaliera Universitaria Integrata Verona
Observed institutions:
University of Verona,
Agostino Gemelli University Polyclinic,
Azienda Sanitaria Unità Locale di Reggio Emilia,
Azienda Ospedaliera Universitaria Integrata Verona
ORCID:
0000-0002-1929-4016
Observed ORCID:
0000-0002-1929-4016
OpenAlex ID:
A5047135191
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer
2017
·
Roberto Iacovelli
, Chiara Ciccarese
, et al.
·
Clinical Genitourinary Cancer
·
184
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
2021
·
Cristina Masini
, Cinzia Iotti
, et al.
·
European Urology
·
122
PDF
Metabolic alterations in renal cell carcinoma
2015
·
Francesco Massari
, Chiara Ciccarese
, et al.
·
Cancer Treatment Reviews
·
107
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives
2018
·
Claudia Mosillo
, Roberto Iacovelli
, et al.
·
Cancer Treatment Reviews
·
52
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies
2017
·
Chiara Ciccarese
, Roberto Iacovelli
, et al.
·
European Journal of Cancer
·
44
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer
2018
·
Roberto Iacovelli
, Chiara Ciccarese
, et al.
·
Targeted Oncology
·
30
Cabozantinib‐related cardiotoxicity: a prospective analysis in a real‐world cohort of metastatic renal cell carcinoma patients
2019
·
Roberto Iacovelli
, Chiara Ciccarese
, et al.
·
British Journal of Clinical Pharmacology
·
29
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
2022
·
Sara Elena Rebuzzi
, Alessio Signori
, et al.
·
Frontiers in Oncology
·
24
PDF
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis
2018
·
Roberto Iacovelli
, Chiara Ciccarese
, et al.
·
Cancer Treatment Reviews
·
24
Role of large language models in the multidisciplinary decision-making process for patients with renal cell carcinoma: a pilot experience
2025
·
Riccardo Bertolo
, Lorenzo De Bon
, et al.
·
npj Precision Oncology
·
21
PDF
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
2022
·
Sara Elena Rebuzzi
, Alessio Signori
, et al.
·
Journal of Translational Medicine
·
21
PDF
Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis
2019
·
Chiara Ciccarese
, Roberto Iacovelli
, et al.
·
Seminars in Oncology
·
18
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer
2016
·
Alessandra Modena
, Roberto Iacovelli
, et al.
·
Targeted Oncology
·
18
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma
2018
·
Davide Bimbatti
, Chiara Ciccarese
, et al.
·
Urologic Oncology Seminars and Original Investigations
·
17
The Incidence and Relative Risk of Pulmonary Toxicity in Patients Treated with Anti-PD1/PD-L1 Therapy for Solid Tumors: A Meta-Analysis of Current Studies
2017
·
Chiara Ciccarese
, Roberto Iacovelli
, et al.
·
Immunotherapy
·
15
PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence
2023
·
Francesco Ditonno
, Alberto Bianchi
, et al.
·
Clinical Genitourinary Cancer
·
14
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer
2019
·
Roberto Iacovelli
, Chiara Ciccarese
, et al.
·
Journal of Immunotherapy
·
14
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study
2024
·
Roberto Iacovelli
, Chiara Ciccarese
, et al.
·
European Urology
·
10
Results of an Italian CORE-IMMUNO study: Safety and clinical-related biomarkers as predictors of immunotherapy (IT) benefit in real-world treatment of various advanced tumors (ATs).
2019
·
Cristina Masini
, Annalisa Berselli
, et al.
·
Journal of Clinical Oncology
·
10
Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide
2015
·
Alessandra Modena
, Chiara Ciccarese
, et al.
·
Expert Review of Anticancer Therapy
·
9
Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis
2025
·
Francesca Zacchi
, Sara Merler
, et al.
·
The Oncologist
·
8
PDF
Renal cell carcinoma in one year: Going inside the news of 2017 – A report of the main advances in RCC cancer research
2018
·
Claudia Mosillo
, Chiara Ciccarese
, et al.
·
Cancer Treatment Reviews
·
6
Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors
2017
·
Roberto Iacovelli
, Chiara Ciccarese
, et al.
·
Journal of Onco-Nephrology
·
6
Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report
2020
·
Giulia Bonfante
, Emanuela Fantinel
, et al.
·
Urology Case Reports
·
5
PDF
1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
2023
·
R. Iacovelli
, C. Ciccarese
, et al.
·
Annals of Oncology
·
4
PDF
Show more works
View as search
Works count:
64
Citation count:
834
H-index:
15
I10-index:
19
Year
Topic
Type